Enzolytics Inc (ENZC)

[foxi]

The way I'm reading it, they found a way to spin off their existing mAbs into a second potential product to treat HIV in a different way/at a different layer.

The IgA1/2 Clone 3 Antibodies provide "immunological defense against an initial exposure to HIV virus at mucosal surfaces" (source) and the older Clone 3 works to "neutralize the Clade C isolate found in Africa, China and India" and also the "Clade B isolate that is predominate in North America and Europe" by targeting HIV immutable sites. (source) I think "mucosal surfaces" is key and that the different classes of mAbs are two separate vectors.

Covid shares some characteristics of HIV so cross-application makes sense. I get the impression ENZC is trying to corner the market with patents rather than delivering the cure, though the world would get the cure in due time whenever ENZC licenses the mAbs.

Now this new info today. Are they abandoning the original mabs and modifying the original Clone 3 to this new version or is this going to be a completely separate version of Clone 3, where they will introduce a preventative Clone 3 as well as a “cure” Clone 3 for people already infected with hiv?